Ads
related to: her2 positive brain metastases survival statistics life expectancy- Clinical Trial Results
Learn About Clinical Trial Results
In Patients Like Yours.
- Request A Rep
Request a Representative & Discover
More About Treatment Option.
- Oncology Co-Pay Program
Downloadable Resources Available
For Your Patients And Practice
- Clinical Trial Design
Learn More About Clinical Trial
And Study Results Today.
- Prescription Info
Find Dosing Guides & Safety
Information Here.
- Ordering Information
Find Out More About Ordering
A Treatment For Your Patients.
- Clinical Trial Results
Search results
Results From The WOW.Com Content Network
A brain metastasis is a cancer that has metastasized (spread) to the brain from another location in the body and is therefore considered a secondary brain tumor. [ 1 ] [ 2 ] The metastasis typically shares a cancer cell type with the original site of the cancer. [ 3 ]
Cancer mortality rates are determined by the relationship of a population's health and lifestyle with their healthcare system. In the United States during 2013–2017, the age-adjusted mortality rate for all types of cancer was 189.5/100,000 for males, and 135.7/100,000 for females. [ 1 ]
Brain and pancreatic cancers have much lower median survival rates which have not improved as dramatically over the last forty years. [4] Indeed, pancreatic cancer has one of the worst survival rates of all cancers. Small cell lung cancer has a five-year survival rate of 4% according to Cancer Centers of America's Website. [5]
This is an accepted version of this page This is the latest accepted revision, reviewed on 3 January 2025. Neoplasm in the brain Medical condition Brain tumor Other names Intracranial neoplasm, brain tumour, brain cancer Brain metastasis in the right cerebral hemisphere from lung cancer, shown on magnetic resonance imaging Specialty Neurosurgery, neuro-oncology Symptoms Vary depending on the ...
HER2 is the target of the monoclonal antibody trastuzumab (marketed as Herceptin). Trastuzumab is effective only in cancers where HER2 is over-expressed. One year of trastuzumab therapy is recommended for all patients with HER2-positive breast cancer who are also receiving chemotherapy. [33] Twelve months of trastuzumab therapy is optimal.
HER2-positive tumors may be treated with the targeted medical therapy (e.g., trastuzumab). Further information: Breast cancer management and Breast cancer § Management Treatment of non-metastatic invasive breast cancer can vary based on staging, usually early stage (stages I and II) versus locally advanced (stage III).
Ads
related to: her2 positive brain metastases survival statistics life expectancy